




RealRate

PHARMACEUTICAL 2015

Anixa Biosciences Inc
Rank 212 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 5.1% points. The greatest weakness of Anixa Biosciences Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 113% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	6,322
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,810
Liabilities, Non-Current	0
Other Assets	2,722
Other Compr. Net Income	0
Other Expenses	3,566
Other Liabilities	3,236
Other Net Income	-3,299
Other Revenues	3,667
Property and Equipment	12
Research and Development	0
Selling, General and Administrative Expense	6,409

Output Variable	Value in 1000 USD
Assets	9,055
Liabilities	5,046
Expenses	9,975
Revenues	3,667
Stockholders Equity	4,010
Net Income	-9,606
Comprehensive Net Income	-9,606
BaseVar	15,521
ECR before Limited Liability	-12%
Economic Capital Ratio	141%